{"id":"azathioprine-or-adalimumab-and-infliximab","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (bacterial, viral, opportunistic)"},{"rate":null,"effect":"Bone marrow suppression / leukopenia"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Nausea / gastrointestinal upset"},{"rate":null,"effect":"Infusion reactions (TNF inhibitors)"}]},"_chembl":{"chemblId":"CHEMBL1201580","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Azathioprine is a purine analog that inhibits T and B cell proliferation, while adalimumab and infliximab are monoclonal antibodies that block tumor necrosis factor-alpha (TNF-α), a key pro-inflammatory cytokine. Together, this combination targets multiple pathways of immune activation to reduce inflammatory disease activity.","oneSentence":"This is a combination therapy using azathioprine (an immunosuppressant) alongside TNF-alpha inhibitors (adalimumab and/or infliximab) to suppress immune-mediated inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:09.055Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory bowel disease (Crohn's disease or ulcerative colitis)"},{"name":"Rheumatoid arthritis"},{"name":"Other TNF-α-responsive autoimmune conditions"}]},"trialDetails":[{"nctId":"NCT06941376","phase":"PHASE2","title":"An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-08-01","conditions":"Relapsing Polychondritis","enrollment":20},{"nctId":"NCT04259138","phase":"PHASE4","title":"Determination of the Optimal Treatment Target in Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alimentiv Inc.","startDate":"2020-02-18","conditions":"Colitis, Ulcerative","enrollment":672},{"nctId":"NCT06673134","phase":"","title":"Prospective Cohort Establishment and Clinical Observation of Children With Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tongji Hospital","startDate":"2023-12-01","conditions":"Crohn Disease","enrollment":100},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT03681652","phase":"","title":"Post-Operative Crohn's Disease Outcome in Children","status":"RECRUITING","sponsor":"Schneider Children's Medical Center, Israel","startDate":"2019-02-11","conditions":"Crohn Disease","enrollment":100},{"nctId":"NCT03591770","phase":"PHASE4","title":"Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib","status":"TERMINATED","sponsor":"Boston Medical Center","startDate":"2019-07-31","conditions":"Inflammatory Bowel Diseases","enrollment":15},{"nctId":"NCT06126835","phase":"","title":"A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Ulcerative Colitis and Their Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2024-08-26","conditions":"Ulcerative Colitis","enrollment":2828},{"nctId":"NCT02332356","phase":"PHASE3","title":"Therapeutic Optimization Study Based on MR Enterocolonography in Patients With Crohn's Disease","status":"UNKNOWN","sponsor":"Tokyo Medical and Dental University","startDate":"2014-09","conditions":"Crohn Disease","enrollment":100},{"nctId":"NCT05928754","phase":"NA","title":"Prospective CoHoRt Of Non-infectious Intermediate, pOsterior or panuveitiS","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","startDate":"2023-09","conditions":"Non-infectious Uveitis","enrollment":2000},{"nctId":"NCT05014555","phase":"","title":"Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease","status":"UNKNOWN","sponsor":"GI Alliance","startDate":"2023-07-05","conditions":"Inflammatory Bowel Diseases","enrollment":400},{"nctId":"NCT03056924","phase":"","title":"Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2017-07-05","conditions":"Inflammatory Bowel Diseases","enrollment":173},{"nctId":"NCT02413047","phase":"NA","title":"Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator","status":"TERMINATED","sponsor":"Indiana University","startDate":"2015-05","conditions":"Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease","enrollment":3},{"nctId":"NCT03886233","phase":"","title":"Treatment Outcome of Uveitis in Autoimmune Diseases","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-03","conditions":"Autoimmune Uveitis","enrollment":1},{"nctId":"NCT02434133","phase":"","title":"Cross Sectional Study of Vaccine Antibody Response in Inflammatory Bowel Disease Patients","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2015-04","conditions":"Inflammatory Bowel Disease (IBD)","enrollment":110},{"nctId":"NCT03580876","phase":"PHASE4","title":"Addition of Azathioprine in IBD Patients With Immunogenic Failure","status":"UNKNOWN","sponsor":"Védrines, Philippe, M.D.","startDate":"2018-07-23","conditions":"Clinical Failure After Switch","enrollment":90},{"nctId":"NCT01505855","phase":"PHASE4","title":"Efficacy Study of Pneumococcal Vaccination in Crohn's Disease","status":"COMPLETED","sponsor":"Kyunghee University Medical Center","startDate":"2011-12","conditions":"Crohn's Disease","enrollment":197},{"nctId":"NCT01860963","phase":"NA","title":"Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls","status":"COMPLETED","sponsor":"Stanford University","startDate":"2010-01","conditions":"Anal Squamous Intraepithelial Lesion (ASIL), HPV DNA","enrollment":310},{"nctId":"NCT01613963","phase":"","title":"Causes of Visual Loss in Retinal Disease","status":"UNKNOWN","sponsor":"Royal Surrey County Hospital NHS Foundation Trust","startDate":"2012-05","conditions":"Uveitis, Scleritis","enrollment":2000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":27049,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"azathioprine or adalimumab and infliximab","genericName":"azathioprine or adalimumab and infliximab","companyName":"Tokyo Medical and Dental University","companyId":"tokyo-medical-and-dental-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination therapy using azathioprine (an immunosuppressant) alongside TNF-alpha inhibitors (adalimumab and/or infliximab) to suppress immune-mediated inflammation. Used for Inflammatory bowel disease (Crohn's disease or ulcerative colitis), Rheumatoid arthritis, Other TNF-α-responsive autoimmune conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}